✨ Free AI Report
Biophytis SA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Biophytis SA
Company Research

Biophytis SA: Business Overview, Financials & Competitive Analysis

Biophytis SA scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech with promising therapeutic platforms addressing large unmet need, but severely capital-constrained and operationally challenged by market conditions. Biophytis has differentiated assets in an important therapeutic area (age-related diseases) and has demonstrated clinical progress with Sarconeos. However, the company faces significant challenges: micromarket capitalization of €3.08m, delisting from NASDAQ.

What is Biophytis SA's industry? Biophytis SA (biophytis.com) operates in Pharmaceuticals. AskCyborg classifies Biophytis SA under Pharmaceuticals in its company registry.

Biophytis is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases, with two programs focused on sarcopenia (loss of muscle functionality) and Age Related Macular Degenerati...

4/ 10Mixed

Cyborg Score thesis

Early-stage biotech with promising therapeutic platforms addressing large unmet need, but severely capital-constrained and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Biophytis SA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Biophytis SA

AskCyborg analysts argue the bull and bear cases for Biophytis SA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Biophytis SA OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Biophytis SA Overview

Pro stress-test →

Biophytis is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases, with two programs focused on sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). The company operates as a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.

Strategic Profile

Pro stress-test →

The company's product pipeline includes Sarconeos (BIO101), a first-in-class drug candidate for the treatment of sarcopenic obesity. The company develops drug candidates based on SARCOB and MACULIA technological platforms. As a clinical-stage biotech with limited market cap, Biophytis faces significant execution risk but operates in the high-value age-related disease therapeutics space.

Competitive Landscape

Pro stress-test →

Biophytis operates in the competitive age-related disease therapeutics space. Direct competitors include Novartis (with anti-aging research initiatives), Unity Biotechnology (senolytic focus), and Juvenescence (longevity-focused biotech platforms). The sarcopenia and ARMD segments also attract attention from larger pharmaceutical players including Eli Lilly (with GLP-1 derivative programs) and Roche (ophthalmology focus). Biophytis' differentiation rests on its dual-platform approach and lead asset stage, though larger-cap competitors have greater resources for clinical advancement.

Industry Context

Biophytis SA operates in Pharmaceuticals.

Key facts

Founded: N/A · Headquarters: Paris, France · Employees: N/A · Revenue: N/A · Market cap: €3.08m

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Biophytis SA.

  • Market cap of €3.08m as of June 2026 indicates severe capital constraints and limited runway for clinical development
  • NASDAQ delisting in 2024 reflects trading volume challenges and limited investor liquidity, now trading on LSE and Euronext Growth Paris
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2024BIO101 commercialization agreement announced with upfront and milestone payments up to €108 million plus royalties
  • April 2024NASDAQ delisting completed; company transitioned to OTC Pink market with plan to move to OTCQB
  • +1 moreTrack every material event for Biophytis SA as it happens. Explore monitoring →
Get alerted when Biophytis SA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Senolytic therapiesCellular senescence targeting for age-related disease→GLP-1 derivative programsMetabolic disease and aging-related conditions→Ophthalmology/ARMD programsAge-related macular degeneration therapies→Longevity platformsAging biology and life extension therapeutics→

Compare Biophytis SA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Biophytis SA operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Biophytis SA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Biophytis SA and its top competitor on Cyborg Score”
“What did Biophytis SA do this quarter?”
“Is Biophytis SA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Biophytis SA do?+
Biophytis is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases, with two programs focused on sarcopenia (loss of muscle functionality) and Age Related Macular Degenerati...
What is Biophytis SA's Cyborg Score?+
Biophytis SA has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Biophytis SA's main competitors?+
Named competitors include Senolytic therapies, GLP-1 derivative programs, Ophthalmology/ARMD programs, Longevity platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Biophytis SA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Biophytis SA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Biophytis SA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.